Trésor Matuvanga Zola (Trésor Zola Matuvanga)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Topics

Respiratory Syndrome Coronavirus

Top Venues

Journal of medical Internet research

BMJ global health

Human vaccines & immunotherapeutics

The Journal of infectious diseases

This page only lists publications with an associated author ORCID identifier.

Publications

Ynke Larivière, Irene Garcia-Fogeda, Trésor Matuvanga Zola, Bernard Isekah Osang'ir, Solange Milolo, Rachel Meta, Primo Kimbulu, Cynthia Robinson, Michael Katwere, Chelsea M McLean, Niel Hens, Junior Rika Matangila, Vivi Maketa, Patrick Mitashi, Hypolite Mavoko Muhindo, Jean-Pierre Van Geertruyden, Pierre van Damme
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo. The Journal of infectious diseases (2023)
Trésor Matuvanga Zola, Reena H Doshi, Albert Muya, Aimé Cikomola, Augustin Milabyo, Pablito Nasaka, Patrick Mitashi, Hypolite Muhindo-Mavoko, Steve Ahuka, Michel Nzaji, Nicole A Hoff, Robert Perry, Elisabeth Mukamba Musenga
Challenges to COVID-19 vaccine introduction in the Democratic Republic of the Congo - a commentary. Human vaccines & immunotherapeutics (2022)
Trésor Matuvanga Zola, Ginger A Johnson, Ynke Larivière, Emmanuel Esanga Longomo, Junior Rika Matangila, Vivi Maketa, Bruno Lapika, Patrick Mitashi, Paula Mc Kenna, Jessie De Bie, Jean-Pierre Van Geertruyden, Pierre van Damme, Hypolite Mavoko Muhindo
Use of Iris Scanning for Biometric Recognition of Healthy Adults Participating in an Ebola Vaccine Trial in the Democratic Republic of the Congo: Mixed Methods Study. Journal of medical Internet research 23 (8) (2021)
Gwen Lemey, Ynke Larivière, Trésor Matuvanga Zola, Vivi Maketa, Junior Rika Matangila, Patrick Mitashi, Peter Vermeiren, Séverine Thys, Jessie De Bie, Hypolite Mavoko Muhindo, Raffaella Ravinetto, Pierre van Damme, Jean-Pierre Van Geertruyden
Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo. BMJ global health 6 (6) (2021)